EQ-5D-5L Health-State Values for the Mexican Population

Gutiérrez-Delgado, Cristina; Galindo-Suárez, Rosa-María; Cruz-Santiago, Cesar; Shah, Koonal; Papadimitropoulos, M.; Feng, Yan; Zamora, Bernarda; Devlin, Nancy

doi:10.1007/s40258-021-00658-0

Cited by 14 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A hybrid model maximizes the available data, increasing precision. It was preferred in ten out of 15 valuation studies using EQ-VT protocol 2.0 or 2.1 [ 21 , 22 , 32 – 35 , 41 , 43 , 44 , 46 – 48 , 51 – 53 ].…”

Section: Discussionmentioning

confidence: 99%

An EQ-5D-5L Value Set for Belgium

Bouckaert

Cleemput

Devriese

et al. 2022

PharmacoEconomics Open

View full text Add to dashboard Cite

Objective This study aimed to establish a Belgian EQ-5D-5L value set based on the preferences of the adult Belgian general population. Methods The most recent EuroQol Valuation Technology (EQ-VT 2.1) protocol for EQ-5D-5L valuation studies was followed. Computer-assisted personal interviews were carried out in a representative sample of the adult Belgian population. Potential respondents were randomly selected from the National Register using a multistage, stratified, cluster sampling with unequal probability design. Each respondent valued 10 or 11 health states using composite time trade-off (cTTO) and 14 health states in seven paired choice tasks using a discrete choice experiment (DCE). Different model specifications were explored and assessed based on logical consistency, goodness of fit, predictive accuracy and theoretical considerations. Results A total of 892 respondents were included in the analyses. The sample was representative of the Belgian adult population in terms of age, sex, region of residence, educational attainment, labour market status, self-assessed health status and health-related quality of life (HRQoL). The preferred model specification was a hybrid (DCE and cTTO data combined) multiplicative eight-coefficient model with intercept random effects and correction for heteroskedasticity. Values range from − 0.532 to 1. Loss of HRQoL is highest in the dimension pain/discomfort, closely followed by anxiety/depression. Conclusions This study developed a Belgian EQ-5D-5L value set, based on the preferences of the Belgian adult general population. It provides opportunities for future clinical and economic evaluations in healthcare, for the measurement of patient-reported outcomes and for population health assessments. Supplementary Information The online version contains supplementary material available at 10.1007/s41669-022-00353-3.

show abstract

Section: Discussionmentioning

confidence: 99%

An EQ-5D-5L Value Set for Belgium

Bouckaert

Cleemput

Devriese

et al. 2022

PharmacoEconomics Open

View full text Add to dashboard Cite

show abstract

“…The design of this ‘lite’ protocol that collected more cTTO data from fewer participants was informed by findings from existing studies. A substantial number of published EQ-5D-5L value sets are based on cTTO data only, such as Canada [ 18 ], China [ 6 ], the Netherlands [ 12 ], Japan [ 8 ], Korea [ 9 ], Uruguay [ 21 ] and, more recently, the USA [ 19 ], Peru [ 22 ], Hungary [ 17 ] and Mexico [ 20 ], enhancing the acceptability of using cTTO data in developing value sets. The attempt to rely on DCE data in a Peruvian valuation study [ 22 ] resulted in marked differences in parameter estimates using DCE only and using cTTO only, potentially casting doubt on the protocol that is less reliant on cTTO.…”

Section: Discussionmentioning

confidence: 99%

“…The EuroQol group developed a standardised valuation study protocol, the EuroQol Valuation Technology (EQ-VT), to create value sets for the EQ-5D-5L [ 5 ]. Following this protocol, EQ-5D-5L value sets have been developed in several countries, mainly in Asia [ 6 – 11 ], Europe [ 12 – 17 ], North America [ 18 – 20 ] and South America [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol

et al. 2021

View full text Add to dashboard Cite

Objective A ‘lite’ version of the EQ-5D-5L valuation protocol, which requires a smaller sample by collecting more data from each participant, was proposed and used to develop an EQ-5D-5L value set for Uganda. Methods Adult respondents from the general Ugandan population were quota sampled based on age and sex. Eligible participants were asked to complete 20 composite time trade-off tasks in the tablet-assisted personal interviews using the offline EuroQol Portable Valuation Technology software under routine quality control. No discrete choice experiment task was administered. The composite time trade-off data were modelled using four additive and two multiplicative regression models. Model performance was evaluated based on face validity, prediction accuracy in cross-validation and in predicting mild health states. The final value set was generated using the best-performing model. Results A representative sample (N = 545) participated in this study. Responses to composite time trade-off tasks from 492 participants were included in the primary analysis. All models showed face validity and generated comparable prediction accuracy. The Tobit model with constrained intercepts and corrected for heteroscedasticity was considered the preferred model for the value set on the basis of better performance. The value set ranges from − 1.116 (state 55555) to 1 (state 11111) with ‘pain/discomfort’ as the most important dimension. Conclusions This is the first EQ-5D-5L valuation study using a ‘lite’ protocol involving composite time trade-off data only. Our results suggest its feasibility in resource-constrained settings. The established EQ-5D-5L value set for Uganda is expected to be used for economic evaluations and decision making in Uganda and the East Africa region.

show abstract

“…Baseline QALY-scores were based on an EQ-5D-5 L study in Mexico. 30 RVGE-related QALY-scores were obtained from studies performed in France and the United Kingdom due to the absence of these QALY data for Mexico ( Table 1 ). 31 , 32 Future QALY losses due to RV deaths that occur during the 1-year time horizon are also included in the outcomes calculations in order to incorporate the foregone quality-adjusted life expectancy associated with death.…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico

Gómez¹,

Velázquez

Guzmán-Holst

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus (RV) infection causes acute rotavirus gastroenteritis (RVGE) in infants. Safe and effective RV vaccines are available, of which Mexico has included one in its national immunization program (NIP) since 2007. Health outcome gains, expressed in quality-adjusted life years (QALYs), and cost improvements are important additional factors for the selection of a NIP vaccine. These two factors were analyzed here for Mexico over one year implementing three RV vaccines: 2-dose Rotarix (HRV), versus 3-dose RotaTeq (HBRV), and 3-dose Rotasiil (BRV-PV), presented in a 1-dose or 2-dose vial). HRV would annually result in discounted QALY gains of 263 extra years compared with the other vaccines by averting an extra 24,022 homecare cases, 10,779 medical visits, 392 hospitalizations, and 12 deaths. From a payer’s perspective and compared with HRV, BRV-PV 2-dose vial and BRV-PV 1-dose vial would annually result in $13,548,179 and $4,633,957 net savings, respectively, while HBRV would result in $3,403,309 extra costs. The societal perspective may also show savings compared with HRV for BRV-PV 2-dose vial of $4,875,860, while BRV-PV 1-dose vial and HBRV may show extra costs of $4,038,363 and $12,075,629 respectively. HRV and HBRV were both approved in Mexico, with HRV requiring less investment than HBRV with higher QALY gains and cost savings. The HRV vaccine produced those higher health gains due to its earlier protection and greater coverage achieved after its schedule completion with two doses only, providing full protection at four months of age instead of longer periods for the other vaccines.

show abstract

EQ-5D-5L Health-State Values for the Mexican Population

Cited by 14 publications

References 25 publications

An EQ-5D-5L Value Set for Belgium

An EQ-5D-5L Value Set for Belgium

Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol

Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico

Contact Info

Product

Resources

About